ASH 2013 Highlights with Novel Therapeutic Agents in AML


ASH 2013 Highlights with Novel Therapeutic Agents in AML
Slides from presentations at ASH 2013 and transcribed comments from a recent interview with Hagop M Kantarjian, MD (1/29/14)
Cortes JE et al. Results of a phase 2 randomized, open-label, study of lower doses of quizartinib (AC220; ASP2689) in subjects with FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML). Proc ASH 2013;Abstract 494.

Kantarjian HM et al. First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML). Proc ASH 2013;Abstract 497.

Marucci G et al. Adding the KIT inhibitor dasatinib (DAS) to standard induction and consolidation therapy for newly diagnosed patients (pts) with core binding factor (CBF) acute myeloid leukemia (AML): Initial results of the CALGB 10801 (Alliance) study. Proc ASH 2013;Abstract 357.

Visani G et al. Low-dose lenalidomide plus low dose cytarabine induce complete remission that can be predicted by genetic profiling in very elderly acute myeloid leukemia patients. Proc ASH 2013;Abstract 496.

Dr Kantarjian is Chairman and Professor in the Leukemia Department at The University of Texas MD Anderson Cancer Center in Houston, Texas.